▲ +233.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Leap Therapeutics in the last 3 months. The average price target is $5.30, with a high forecast of $8.00 and a low forecast of $2.50. The average price target represents a 233.33% upside from the last price of $1.59.
The current consensus among 5 polled investment analysts is to buy stock in Leap Therapeutics. This Buy consensus rating has held steady for over two years.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.